MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract...

MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that an abstract regarding a mouse model study that examined the potential clinical efficacy of MN-166 for glioblastoma has been accepted for presentation at the 2017 American Society of Clinical Oncology Annual Meeting to be held June 2-6, 2017 in Chicago, Illinois.



from Biotech News